References
- 1. Weller, I.V. & Williams, I.G. (2001). ABC of AIDS. Antiretroviral drugs. BMJ. 322(7299), 1410-1412
- 2. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Retrieved from http://aidsinfo.nih.gov/guidelines
- 3. Flexner, C. (1998). HIV protease inhibitors. N Engl J Med. 338, 1281-1293
- 4. "U.S. FDA approves GlaxoSmithKline's HIV drug Tivicay". From: Reuters. 12 August 2013.Retrieved 13 February 2013
- 5. EMA Tivicay information page. Retrieved from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/002753/human_med_001720. jsp&mid=WC0b01ac058001d124
- 6. CSID: 25051637. (2014). Retrieved from http://www.chemspider.com/Chemical-Structure.25051637.html
- 7. Hare, S., Smith, S.J., Métifiot, M., Jaxa-Chamiec, A., Pommier, Y., Hughes, S.H. & Cherepanov, P. (2011). Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 80(4), 565-572
- 8. Cottrell, M.L., Hadzic, T. & Kashuba, A.D. (2013). Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 52(11), 981-994
- 9. FDA approves new drug to treat HIV infection. (2013). Retrieved from http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ ucm364744.html
- 10. Min, S., Song, I. & Borland, J. et al. (2010). Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 54, 254-258
- 11. Song, I., Borland, J. & Chen, S. et al. (2012). Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 56, 1627-1629
- 12. Letendre, S., Mills, A., Tashima, K., Thomas, D., Min, S., Chen, S., Song, I. & Piscitelli, S. (2013). Distribution and Antiviral Activity in Cerebrospinal Fluid (CSF) of the Integrase Inhibitor, Dolutegravir (DTG): ING116070 Week 16 Results. CROI 2013. Poster 178LB
- 13. van Lunzen, J., Maggiolo, F., Arribas, J.R., Rakhmanova, A., Yeni, P., Young, B., Rockstroh, J.K., Almond, S., Song, I., Brothers, C. & Min, S. (2012). Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomized, phase 2b trial. Lancet Infect Dis. 12(2), 111-118
- 14. Raffi, F., Rachlis, A., Stellbrink, H.J., Hardy, W.D., Torti, C., Orkin, C., Bloch, M., Podzamczer, D., Pokrovsky, V., Pulido, F., Almond, S., Margolis, D., Brennan, C. & Min, S. (2013). SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviralnaive adults with HIV-1 infection: 48 week results from the randomized, double-blind, noninferiority SPRING-2 study. Lancet. 381(9868), 735-743
- 15. Raffi, F., Jaeger, H., Quiros-Roldan, E., Albrecht, H., Belonosova, E., Gatell, J.M., Baril, J.G., Domingo, P., Brennan, C., Almond, S. & Min, S. (2013). Extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomized, double-blind, noninferiority trial. Lancet Infect Dis. 13(11), 927-935
- 16. Walmsley, S.L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., Pappa, K., Wynne, B., Min, S. & Nichols, G. (2013). SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 369(19), 1807-1818
- 17. Clotet, B., Feinberg, J., van Lunzen, J., Khuong-Josses, M.A., Antinori, A., Dumitru, I., Pokrovskiy, V., Fehr, J., Ortiz, R., Saag, M., Harris, J., Brennan, C., Fujiwara, T. & Min, S. (2014). ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomized open-label phase 3b study. Lancet. 383(9936), 2222-2231
- 18. Cahn, P., Pozniak, A.L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J.F., Richmond, G., Buendia, C.B., Fourie, J., Ramgopal, M., Hagins, D., Felizarta, F., Madruga, J., Reuter, T., Newman, T., Small, C.B., Lombaard, J., Grinsztejn, B., Dorey, D., Underwood, M., Griffith, S. & Min, S. (2013). Extended SAILING Study Team. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomized, doubleblind, non-inferiority SAILING study. Lancet. 382(9893), 700-708
- 19. Castagna, A., Maggiolo, F., Penco, G., Wright, D., Mills, A., Grossberg, R., Molina, J.M., Chas, J., Durant, J., Moreno, S., Doroana, M., Ait- Khaled, M., Huang, J., Min, S., Song, I., Vavro, C., Nichols, G. & Yeo, J.M. (2014). VIKING-3 Study Group. Dolutegravir in antiretroviralexperienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 210(3), 354-362
- 20. Eron, J., Clotet, B., Durant, J., Katlama, C., Kumar, P., Lazzarin, A., Poizot-Martin, I., Richmond, G., Soriano, V., Ait-Khaled, M., Fujiwara, T., Huang, J., Min, S., Vavro, C. & Yeo, J. for the VIKING Study Group (2013). Safety and efficacy of dolutegravir in treatmentexperienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 207(5), 740-748
- 21. Cutillas, V., Mesplede, T., Anstett, K., Hassounah, S. & Wainberg, M.A. (2014). The addition of R262K to the H51Y mutation in HIV-1 subtype B integrase confers low-level resistance against dolutegravir. Antimicrob Agents Chemother. pii: AAC.04274-14. [Epub ahead of print]
- 22. Hardy, I., Brenner, B., Quashie, P., Thomas, R., Petropoulos, C., Huang, W., Moisi, D., Wainberg, M.A. & Roger, M. (2014). Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother. pii: dku387. [Epub ahead of print]
- 23. Hightower, K.E., Wang, R., Deanda, F., Johns, B.A., Weaver, K., Shen, Y., Tomberlin, G.H., Carter, H.L. 3rd, Broderick, T., Sigethy, S., Seki, T., Kobayashi, M. & Underwood, M.R. (2011). Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 55(10), 4552-4559
- 24. Underwood, M.R., Johns, B.A., Sato, A., Martin, J.N., Deeks, S.G. & Fujiwara, T. (2012). The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults. J Acquir Immune Defic Syndr. 61(3), 297-301
- 25. Johnson, M., Borland, J., Chen, S., Savina, P., Wynne, B. & Piscitelli, S. (2014). Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir. Br J ClinPharmacol. 78(5), 1043-1049
- 26. Simeprevir (2013). FDA Antiviral Drugs Advisory Committee Meeting Briefing Document
- 27. Sofosbuvir for the Treatment of Chronic Hepatitis C Infection, Gilead Sciences (2013). Retrieved from http://www.gilead.com/news/press-releases/2013/12/us-food-and-drugadministration-approves-gileads-sovaldisofosbuvir-for-the-treatment-of-chronichepatitis-c
- 28. Dow, D.E. & Bartlett, J.A. (2014). Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV. Infect Dis Ther. 3, 83-102